Skip to main content
. Author manuscript; available in PMC: 2010 Mar 2.
Published in final edited form as: Nat Clin Pract Oncol. 2008 Jan;5(1):44–54. doi: 10.1038/ncponc0982

Figure 4.

Figure 4

Monitoring of target inhibition by dynamic contrast-enhanced MRI. At baseline (top row), the multiple liver metastases (arrows) demonstrate intense contrast enhancement. Following treatment with the VEGF receptor protein kinase inhibitor PTK/ZK, the liver metastases demonstrate no visible contrast enhancement, indicating a marked decrease in vascular permeability or perfusion. Permission obtained from the American Society of Clinical Oncology © Morgan B et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955–3964.

HHS Vulnerability Disclosure